NHS England

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab).  The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma who are inadequately controlled with high dose inhaled […]

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who […]

England will become the first country in Europe to roll out darolutamide (Nubeqa) to patients whose prostate cancer has spread to other parts of the body.  The drug works by blocking androgen receptors in cancer cells, which in turn blocks the effect of testosterone that allows the cancer cells to survive and multiply. Studies show […]